



SYMPOSIUM 2. Training of young Pharmacoepidemiologists in Asia-Pacific regions: Challenges and future potentials

Moderators

Edward Lai, National Cheng Kung University, Taiwan



Edward is an Associate Professor at the School of Pharmacy, National Cheng Kung University, Taiwan. He has expertise in the use of a variety of healthcare databases across Asia, Oceania, North America and Europe in the conduct of international multi-database pharmacoepidemiologic research. His research interests include safety and comparative effectiveness of psychotropic, rheumatologic and oncologic medications. He has published 90+ research articles on top journals such as BMJ, Annals of Internal Medicine and Lancet Psychiatry. He has served as an Associate Editor of Pharmacoepidemiology and Drug Safety since 2013. He had served as the chair of Asian Pharmacoepidemiology Network (AsPEN) (2016-2018). He is an active member of the Neurological and Mental Health Global Epidemiology Network (NeuroGEN).

Daniel Tsai, National Cheng Kung University, Taiwan student chapter



Daniel Tsai is a clinical pharmacist, and he received his master's degree in pharmacoepidemiology, majoring in big data analysis. Daniel is the educational & academic lead at ISPE student council. He primarily assesses the effectiveness, safety, and risk factors for medication. Moreover, he uses the claims database to evaluate rare neurological diseases. Furthermore, he uses the electronic health record for validation to integrate big and small databases. On the other hand, he joined the artificial intelligence BESTMED project for smart techniques in pharmaceutical care.



Alice Su, National Cheng Kung University, Taiwan student chapter



Alice is a PhD student in the Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University (NCKU). Her research is focused on pharmacoepidemiology and pharmacoconomics. She is also a qualified pharmacist in Taiwan, and the vice president of NCKU student chapter, which has initiated the pharmacoepidemiology in Taiwan.

Nai-Yu Chen, National Cheng Kung University, Taiwan student chapter



Nai-Yu Chen, Master of Clinical Pharmacy is a Ph.D. student in the National Cheng Kung University, Institute of Clinical Pharmacy and Pharmaceutical Sciences and a pharmacist in Kaohsiung Veterans General Hospital, department of pharmacy. She is also a member of NCKU student chapter. Her research focus on evaluating drug safety, drug utilization, biological and comparative effectiveness study. As a clinical pharmacist, she takes care of patients in the respiratory intensive care unit and gives clinical advice on the use of medications. As a hospital pharmacy mentor, she also teaches pharmacy students the knowledge in clinical settings.

Steven Shen, National Cheng Kung University, Taiwan student chapter




student chapter.

Steven, Chin-Yao, Shen is currently pursuing a PhD in pharmacoepidemiology at National Cheng Kung University (NCKU). He is a registered pharmacist and had further obtained his Masters of Clinical Pharmacy from NCKU. His research interests focus on drug utilization, comparative effectiveness research, distributed network approach and has experiences in data analysis methods such as SAS. He was awarded the Andrew McAfee Award from International Society for Pharmacoepidemiology in 2021. Steven is also a co-chair of the NCKU



Speakers

Tobias Gerhard FISPE, President, International Society for Pharmacoepidemiology



Dr. Gerhard is a pharmacoepidemiologist and the Founding Director of the Rutgers Center for Pharmacoepidemiology and Treatment Science (PETS). He received his pharmacy degree from the University of Freiburg, Germany, and his PhD in pharmacoepidemiology from the University of Florida. Dr. Gerhard's work focuses on the development and evaluation of modern pharmacoepidemiologic methods with applications in mental health and geriatric pharmacotherapy. He has extensive experience working with large claims and EHR datasets and has published widely on use, safety, and outcomes of therapeutics, particularly of psychotropic medications in vulnerable populations. His work has been funded by NIA, NIMH, AHRQ, PCORI, and by multiple foundations. Currently, he serves as PI of two R01 awards from the NIA and as subcontract PI for several other NIH-funded projects. Dr. Gerhard is a Fellow of the International Society for Pharmacoepidemiology (ISPE) and its current President and serves on committees for FDA and the National Academies of Sciences, Engineering, and Medicine (NASEM).


Sebastian Jugl, University of Florida, USA and College of Pharmacy, Germany



Sebastian Jugl is a pharmacist, a PhD student in the Department of Pharmaceutical Outcomes and Policy, in the College of Pharmacy at the University of Florida and an author for the German Pharmaceutical Association (DPhG). He is particularly interested in applying pharmacoepidemiologic methods to investigate drug utilization, drug safety & effectiveness, and the effects of state and federal laws in the area of oncology, women's health, and medical cannabis research. During his leadership of the ISPE student council, the student council was heavily invested in identifying student's needs & interests in the society, and developing means to ensure that those will be met in the future (e.g., by creating SISPEs 5-year Agenda, and establishing additional positions in the student council).



Miyuki Hsing-Chun Hsieh, National Cheng Kung University, Taiwan



Miyuki Hsing-Chun Hsieh is now a current PhD candidate at National Chong Kung University in Tainan, Taiwan. Her research interest is mainly focused on drug safety, including utilizing hypothesis-free methods to identify drug safety signals, and utilizing different pharmacoepidemiological designs to evaluate adverse drug reactions. Ms. Miyuki is also the Chair of the ISPE Student Council and works hard with student council members in promoting student events and enhancing student involvement in society activities.

Nathorn (Nui) Chaiyakunapruk, University of Utah College of Pharmacy, USA; Thailand



Nathorn Chaiyakunapruk is a Professor in the Department of Pharmacotherapy at the University of Utah College of Pharmacy in Salt Lake City. He earned a Doctorate of Pharmacy (PharmD) from the University of Wisconsin-Madison, and his PhD in Pharmaceutical Outcomes Research and Policy Program from the University of Washington. His expertise is in Health Technology Assessment and Global Health. He has applied several HTA methodologies (Health Economics, Real World Data Analysis, and Evidence Synthesis: systematic review and classical/network meta-analysis/ Umbrella review) to support national and global policy. His research has been funded through grants from the World Health Organization, Centers for Disease Control and Prevention, Wellcome Trust, US National Human Genome Research Institute, and the National Institute for Health Research UK. Dr. Chaiyakunapruk has an H-index of 48 and is an author of more than 300 international publications in peer-reviewed.



Nicole Pratt, Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia



Professor Nicole Pratt is the Deputy Director of the Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Fellow of the International Society of Pharmacoepidemiology (FISPE). She is an expert in biostatistics specialising in development of methods to study the effects of medicines and medical devices in large linked healthcare datasets.

Swu-Jane Lin, University of Illinois, Chicago, USA; Taiwan



Dr. Swu-Jane Lin is a senior scientist at Hind T. Hatoum & Company, Chicago, USA. She is also an adjunct faculty with the University of Illinois at Chicago, Chicago, USA, and National Cheng Kung University, Tainan, Taiwan. She received her Ph.D. degree from the University of Illinois at Chicago in pharmacy administration, specialized in health outcomes research, and the Master degree in public health from National Taiwan University, Taipei, Taiwan. Her research interests and expertise lie in pharmacoconomics and pharmacoepidemiology. She has conducted research projects with big data, clinical trial data, and surveys, focusing on the following areas: (1) pharmaceutical treatments and patient outcomes, (2) prescribing pattern and geographic variation in medication use, (3) adverse drug events, and (4) budget impact forecasts of new drugs.